Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies

por Chey, W. D., Dove, L. S., Andrae, D. A., Covington, P. S.
Publicado 2017

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist

por Levy-Cooperman, N., McIntyre, G., Bonifacio, L., McDonnell, M., Davenport, J. M., Covington, P. S., Dove, L. S., Sellers, E. M.
Publicado 2016